Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that new therapies will transform the historically stagnant acute ischemic stroke arena into a fledgling market.

"The uptake of neuroprotective drugs such as AstraZeneca/Renovis's NXY-059 and novel thrombolytic drugs such as Forest/Paion's desmoteplase that are priced at a premium over traditional treatments such as rt-PA will grow the acute ischemic stroke market over the next ten years," said Julie Kerner, analyst at Decision Resources, Inc.

The new Pharmacor study entitled Acute Ischemic Stroke also found that experts are generally unenthusiastic about campaigns to improve emergency transport of acute ischemic stroke patients, because so few time-sensitive treatments are available. However, with the approval of emerging therapies with longer treatment windows, efforts to improve emergency transport will yield better outcomes. These initiatives will increase the drug-treated population and increase drug sales.

Cost of Disability Associated with Acute Ischemic Stroke

Acute ischemic stroke is the third-leading cause of death in the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) and the leading cause of severe neurological disability worldwide. Long-term disability is the most devastating and costly result of acute ischemic stroke. In 2005, according to the America Heart Association, the treatment of stroke and the long-term care required for its victims will cost the United States more than $50 billion.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Following Claritin's Lead, Second-Generation Antihistamines Switching to Over-the-Counter Status Drive the Allergic Rhinitis Prescription Drug Market into a Downward Spiral

View Now